TY - JOUR
T1 - Targeting C-fibers for peripheral acting anti-tussive drugs
AU - Patil, Mayur J.
AU - Sun, Hui
AU - Ru, Fei
AU - Meeker, Sonya
AU - Undem, Bradley J.
N1 - Funding Information:
This work was supported by NIH RO1HL137807 and R01HL122228 to BJU. MJP was partly also supported by Dr. David Marsh Symposium Research Award, Johns Hopkins University (Asthma and allergy Division).
Funding Information:
This work was supported by NIH RO1HL137807 and R01HL122228 to BJU. MJP was partly also supported by Dr. David Marsh Symposium Research Award, Johns Hopkins University (Asthma and allergy Division).
Publisher Copyright:
© 2019
PY - 2019/6
Y1 - 2019/6
N2 - Activation of vagal C-fibers is likely involved in some types of pathological coughing, especially coughing that is associated with airway inflammation. This is because stimulation of vagal C-fibers leads to strong urge to cough sensations, and because C-fiber terminals can be strongly activated by mediators associated with airway inflammation. The most direct manner in which a given mediator can activate a C-fiber terminal is through interacting with its receptor expressed in the terminal membrane. The agonist-receptor interaction then must lead to the opening (or potentially closing) of ion channels that lead to a membrane depolarization. This depolarization is referred to as a generator potential. If, and only if, the generator potential reaches the voltage necessary to activate voltage-gated sodium channels, action potentials are initiated and conducted to the central terminals within the CNS. Therefore, there are three target areas to block the inflammatory mediator induced activation of C-fiber terminals. First, at the level of the mediator-receptor interaction, secondly at the level of the generator potential, and third at the level of the voltage-gated sodium channels. Here we provide a brief overview of each of these therapeutic strategies.
AB - Activation of vagal C-fibers is likely involved in some types of pathological coughing, especially coughing that is associated with airway inflammation. This is because stimulation of vagal C-fibers leads to strong urge to cough sensations, and because C-fiber terminals can be strongly activated by mediators associated with airway inflammation. The most direct manner in which a given mediator can activate a C-fiber terminal is through interacting with its receptor expressed in the terminal membrane. The agonist-receptor interaction then must lead to the opening (or potentially closing) of ion channels that lead to a membrane depolarization. This depolarization is referred to as a generator potential. If, and only if, the generator potential reaches the voltage necessary to activate voltage-gated sodium channels, action potentials are initiated and conducted to the central terminals within the CNS. Therefore, there are three target areas to block the inflammatory mediator induced activation of C-fiber terminals. First, at the level of the mediator-receptor interaction, secondly at the level of the generator potential, and third at the level of the voltage-gated sodium channels. Here we provide a brief overview of each of these therapeutic strategies.
UR - http://www.scopus.com/inward/record.url?scp=85062880049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062880049&partnerID=8YFLogxK
U2 - 10.1016/j.pupt.2019.03.002
DO - 10.1016/j.pupt.2019.03.002
M3 - Review article
C2 - 30872160
AN - SCOPUS:85062880049
SN - 1094-5539
VL - 56
SP - 15
EP - 19
JO - Pulmonary Pharmacology and Therapeutics
JF - Pulmonary Pharmacology and Therapeutics
ER -